SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheuma...Read Press Release from
May 6, 2020
Company Presented Positive Data on RA 24-Month Follow-up Study and Current Crohn’s Disease Study
Valencia, CA – January 14, 2018 – SetPoint Medical, a clinical-stage biomedical technology company developing an implantable bioelectronic medicine therapy for chronic inflammatory diseases, presented positive data from two clinical studies in rheumatoid arthritis (RA) and Crohn’s disease (CD) at the North American Neuromodulation Society (NANS) annual meeting, held January 11-14, 2018 in Las Vegas.
Both studies use an implanted device to deliver digital doses of electricity, stimulating the vagus nerve with timed electrical pulses, activating the body’s natural Inflammatory Reflex to produce a systemic anti-inflammatory effect.
“The data presented at NAHMS and our ongoing human studies support SetPoint’s development of bioelectronic medicines designed to improve the lives of people suffering from chronic inflammatory diseases. Activation of the Inflammatory Reflex via vagal nerve stimulation provides a novel approach to treating inflammatory diseases currently treated with potent and targeted expensive drugs like TNFa inhibitors,” said David Chernoff, MD, Chief Medical Officer of SetPoint Medical. “In addition to the ongoing Crohn’s study, we are pleased to have initiated a pilot trial in the U.S. for patients with drug-refractory rheumatoid arthritis using SetPoint’s proprietary bioelectronics vagal nerve stimulation device. We look forward to reporting pilot data later this year.”
SetPoint is developing a novel proprietary bioelectronic medicine platform that activates the body’s natural Inflammatory Reflex in order to activate systemic anti-inflammatory pathways. The emerging field of bioelectronic medicine aims to address unmet patient needs by delivering targeted digital doses to modulate physiological circuits for treatment of diseases historically treated with drugs.
About SetPoint Medical
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative treatment for rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy.
SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific. For more information, visit www.setpointmedical.com.
# # #